Novelion’s Myalepta gets European approval to treat generalized and partial lipodystrophy

07:13 EDT 1 Aug 2018 | Pharmaceutical Business Review

Myalepta has been approved as an adjunct to diet, as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with confirmed congenital generalized

More From BioPortfolio on "Novelion’s Myalepta gets European approval to treat generalized and partial lipodystrophy"